secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016635
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics Q2 2022 net loss $22.7M; revenue down $2.5M YoY
------------------------------------------------------------------

- Net loss of $22.7M vs $15.2M in Q2 2021; R&D flat at $13.9M; G&A up to $8.2M.
- Revenue fell primarily due to Takeda agreement amendment; prior period had $1.8M PPP loan gain.
- Cash $104.7M as of June 30, 2022 (down from $133.5M Dec 2021); funds operations into Q1 2024.
- On track to start enrollment in PRISM4 Phase 3 CP101 trial in H2 2022; topline data expected H1 2024.
- PRISM-EXT results accepted for ACG 2022; FIN-211 IND submission on track for Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022016635/0000950170-22-016635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022016635/fnch-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer